Recent breakthroughs in oncology provide new hope for patients with liver cancer. Specifically, a landmark phase 2-3 trial evaluated the efficacy of neoadjuvant GOLP therapy in treating resectable high-risk intrahepatic cholangiocarcinoma. This regimen combines chemotherapy with targeted agents and immunotherapy to reduce tumor burden before surgery.
Clinical Outcomes of Neoadjuvant GOLP Therapy
The study randomized 178 patients into two distinct treatment arms. Half of the participants received three cycles of the GOLP regimen. In contrast, the other half underwent immediate curative resection. Both groups received adjuvant capecitabine after their operations. Consequently, the researchers compared event-free survival between the two cohorts.
The results were clinically significant. Patients in the neoadjuvant group achieved a median event-free survival of 18.0 months. Meanwhile, those in the control group reached only 8.7 months. This striking difference represents a major advance in surgical oncology. Furthermore, the overall survival data favored the neoadjuvant approach.
Safety and Practical Considerations
Safety remains a primary concern for any intensive multi-drug regimen. In this trial, approximately 26% of patients experienced grade 3 or higher treatment-related adverse events. However, the safety profile was considered manageable within a specialized clinical setting. Clinicians must monitor patients closely for potential toxicity during the nine-week preoperative phase.
Ultimately, this study supports the shift toward perioperative systemic therapy. By incorporating lenvatinib and toripalimab, the GOLP regimen addresses the aggressive nature of high-risk disease. It provides a new standard for future clinical practice in biliary tract cancers.
Frequently Asked Questions
Q1: What specific drugs comprise the GOLP regimen?
The GOLP regimen includes gemcitabine and oxaliplatin (chemotherapy), lenvatinib (a targeted kinase inhibitor), and toripalimab (an anti-PD-1 immunotherapy).
Q2: Who are the ideal candidates for this neoadjuvant treatment?
This treatment is specifically designed for patients with intrahepatic cholangiocarcinoma who are candidates for surgery but have high-risk factors for recurrence.
References
- Shi GM et al. Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma. N Engl J Med. 2026 Mar 05. doi: 10.1056/NEJMoa2513918. PMID: 41780001.